Market Research Report
In Situ Hybridization Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)
|In Situ Hybridization Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)|
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 120 Pages
Delivery time: 2-3 business days
The in situ hybridization market studied is expected to register with an anticipated CAGR of 7.2% during the forecast period of 2021-2026.
The COVID-19 pandemic is expected to have a significant effect on the market. To keep pace with increased testing norms to detect suspected cases of COVID-19, with the emergence of the SARS-CoV-2 virus, already increased lab testing demands grew even more across the world. The demand for clinical diagnosis has thus grown to 26-50%. The recent outbreak of COVID-19 is expected to positively impact the in-situ hybridization industry, as it involves the testing of various biological samples. This development is expected to aid the detection of infectious diseases, such as COVID-19, and testing remains a crucial step in controlling the COVID-19 disease mass transmission. The manufacturers and government have also made rising investments that have shown a high positive impact on the market. For instance, in March 2020, Amazon Web Services announced that it had invested USD 20 million to accelerate COVID-19 research, diagnostics, and testing services. In March 2020, the Innovative Medicines Initiative (IMI) supported through the European Commission's Horizon 2020 Framework Programme for Research and Innovation announced a EUR 72 million funding to 5 organizations working to innovate diagnostic portfolios for COVID-19. Additionally, in April 2020, researchers from the Department of Pathology and Laboratory Medicine at the University of Pennsylvania announced that they had started a project titled 'Applications of RNA FISH to visualize SARS-CoV-2 for diagnostics and CRISPR screening for therapeutics'. Developments such as these are expected to boost market growth during the forecast period.
The increasing incidence of cancer, infectious diseases, and genetic disorders and the increasing awareness of cancer therapeutics are the major drivers for the growth of In Situ Hybridization Market. According to Globocan 2020, new cancer cases diagnosed in the year 2020 accounted for 19,292,789 in 2020 worldwide, with 9,958,133 deaths due to cancers globally. Among all cancers, breast cancer accounted to 2,261, 419 new cancer cases, followed by lung (2,206,771), Prostate (1,414,259) and colon (1,148,515) new cases in 2020. The high incidence of cancers globally has resulted in an increasing demand for personalized diagnostic tests, which further boosts the research for the FISH and CISH tests. Additionally, in 2018, the WHO estimated that nearly 10,000 human diseases are monogenic, i.e., diseases occurring due to modifications in a single gene in the body's cells. Thus, the increasing prevalence of monogenic diseases also drives the studied market. The emerging trend in research and the launch of new products are driving the studied market significantly. Hence, these factors are expected to increase the demand for in situ hybridization over the forecast period.
The in situ hybridization market is expected to grow due to the high prevalence of cancer worldwide. Rising cases of cancer are expected to positively affect demand for clinical diagnostics. According to Globocan 2020 figures, there were 19,292,789 new cancer cases diagnosed worldwide in 2020. The figures from Globocan 2020 also pointed out that the incidence of new cancer cases in very high HDI (Human Development Index) countries was 8,934,818, followed by 7,371,321 in high HDI countries. Medium and low HDI countries had 2,326,749 and 650,423 cases, respectively. The high incidence of cancer cases in countries with higher standards of living is primarily due to the availability and access to better diagnostic procedures. Clinical cancer diagnostics equipment like in situ hybridization is used extensively for these procedures, due to which their demand is expected to increase during the forecast period. Due to its ability to early-stage detection of cancer, In Situ Hybridization is expected to witness a robust growth rate. In situ hybridization, the FISH technique is used in the diagnosis of HER2 positive breast cancers. The sensitivity, specificity, and speed of this assay have made in situ hybridization an important cytogenetic tool in the diagnosis of tumors. Thus, these factors are expected to positively impact the cancer segment of the in situ hybridization market.
North America is expected to account for the major share in the in situ hybridization market, owing to the higher incidence of cancer in the region, the prevalence of infectious diseases and genetic disorders in the region. According to Globocan 2020 reports, the incidence of cancer in 2020 in the United States was 362.2 per 100,000 population and 348.0 per 100,000 population in Canada. High incidence rates of cancer are expected to positively affect market demand for in situ hybridization products during the forecast period. Another key market driver is the increase in the approval rate of In Situ Hybridization products by regulatory and governing authorities. For example, in 2019, Oxford Gene Technology received a United States Food & Drug Administration approval for eight Cytocell FISH probes used to detect acute myeloid leukemia and myelodysplastic syndromes. North America is also a hub for large numbers of clinical research laboratories and institutes, and hence focus on new product development is expected to occur. Thus, given the above factors, North America is expected to dominatethe in situ hybridization market over the forecast period.
The in situ hybridization market is highly competitive. The major players operating globally in the in situ hybridization market are Abnova Corporation, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, Biocare Medical LLC., Genemed Biotechnologies Inc., Thermo Fisher Scientific Inc., Biogenex Laboratories, Zytomed Systems GmbH, Creative Bioarray, and Bio SB Inc.
Initiatives in strategies such as new product development, collaborations, acquisitions, and funding in research and development are adopted by key players to secure their positions in the global market. For example, in July 2020, Creative Bioarray, a US-based biotechnology company, developed M-FISH, a general-purpose tool for precise chromosome separation and rapid chromosome classification, helping speed up the workflow.